Oncologics led all classes in spending in 2014 with $32.3Bn in spending, or $43.4Bn including supportive care treatments.

1. HEALTHCARE COSTS AND SPENDING ON MEDICINES
Page 12
Source: IMS Health, National Sales Perspectives, Dec 2014
43.4
38.5
36.335.7
34.9
Supportive Care Cytotoxics Hormonal TherapiesTargeted Therapies
2010 2011 2012 2013 2014
12.3 11.6 10.7 10.7 11.1
7.4 7.7
7.0 6.5 6.5
12.6 14.4 16.7 19.1
22.9
2.6 2.0 1.9
2.2
2.9
Oncologics spending reached $43.4 billion in 2014 lifted by
new melanoma, lung, breast and prostate cancer therapies
Therapeutic Oncology and Supportive Care Spending US$Bn
•• Oncologics led all classes in spending in
2014 with $32.3Bn in spending, or $43.4Bn
including supportive care treatments.
•• Spending grew by nearly $4.9Bn, mostly
from new targeted therapies, which had the
fourth straight year of $1Bn or more growth
from new brands, and many of those earlier
medicines have continued to expand usage
and contribute more to spending.
•• Treatment options launched in the last two
years account for 30% of spending increases.
•• Supportive care treatments such as
erythropoeitins, anti-nauseants, and
bisphosphonates contributed little to
spending growth but often allow patients to
continue on other treatments.
•• Granix, a non-original version of the biologic
Neupogen, used to reduce the risk of infection
during chemotherapy, became available in
November 2013 and now accounts for 11% of
filgrastim volumes.
Chart notes:
Therapeutic oncology defined as EphMRA ATC classification L1 - cytotoxics, L2 hormonal treatments, V3C radiotherapeutics, as well as molecules
classified elsewhere noted to be therapeutic oncolgoics (lenalidomide, denosumab (when used for bone metastases it is marketed as Xgeva),
aldesleukin, pomalidomide). Supportive care includes erythropoeitins, colony-stimulating factors, anti-nauseants for cancer, and chemotherapy
protectants.
Medicines Use and Spending Shifts. Report by the IMS Institute for Healthcare Informatics.